Recent Finacing
Recent Raise
Regimmune develops antigen-specific immune-regulatory therapeutics using its reVax platform to induce regulatory T cells, advancing programs for graft‑versus‑host disease, allergies, type 1 diabetes, and celiac disease.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors